Profile data is unavailable for this security.
About the company
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision oncology medicines. The Company uses its precision medicine platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a potentially registrational Phase 2 trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore substantially improve the clinical overall response rate (ORR) and has the potential to enable expedited drug development. Its preclinical program, ACR-2316, is advancing in IND-enabling studies. It is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate.
- Revenue in USD (TTM)0.00
- Net income in USD-64.12m
- Incorporated2018
- Employees58.00
- LocationAcrivon Therapeutics Inc480 Arsenal Way, Suite 100WATERTOWN 02472United StatesUSA
- Phone+1 (617) 207-8979
- Fax+1 (302) 636-5454
- Websitehttps://acrivon.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eliem Therapeutics Inc | 0.00 | -14.53m | 222.84m | 9.00 | -- | 2.00 | -- | -- | -0.5347 | -0.5347 | 0.00 | 3.84 | 0.00 | -- | -- | 0.00 | -12.55 | -- | -13.00 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.38 | -- | -- | -- |
| Conduit Pharmaceuticals Inc | -100.00bn | -100.00bn | 223.70m | -- | -- | -- | -- | -- | -- | -- | -- | -0.042 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Akebia Therapeutics Inc | 187.23m | -43.03m | 224.27m | 167.00 | -- | -- | -- | 1.20 | -0.2213 | -0.2213 | 0.9726 | -0.1301 | 0.7454 | 1.34 | 8.43 | 1,121,108.00 | -17.13 | -37.42 | -24.39 | -56.00 | 83.44 | 69.13 | -22.98 | -82.25 | 1.31 | -4.82 | 10.44 | -- | -33.46 | -1.30 | 44.89 | -- | -- | -- |
| Aldeyra Therapeutics Inc | 0.00 | -30.01m | 225.18m | 10.00 | -- | 1.99 | -- | -- | -0.5080 | -0.5080 | 0.00 | 1.91 | 0.00 | -- | -- | 0.00 | -19.39 | -36.79 | -22.08 | -40.77 | -- | -- | -- | -- | -- | -- | 0.1182 | -- | -- | -- | 39.47 | -- | -- | -- |
| Rani Therapeutics Holdings Inc | 0.00 | -33.08m | 231.93m | 140.00 | -- | 29.99 | -- | -- | -1.29 | -1.29 | 0.00 | 0.1534 | 0.00 | -- | -- | 0.00 | -87.80 | -- | -140.92 | -- | -- | -- | -- | -- | -- | -28.75 | 0.6695 | -- | -- | -- | -11.06 | -- | -- | -- |
| Design Therapeutics Inc | 0.00 | -58.67m | 237.84m | 57.00 | -- | 0.8823 | -- | -- | -1.05 | -1.05 | 0.00 | 4.77 | 0.00 | -- | -- | 0.00 | -19.44 | -- | -19.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.61 | -- | -- | -- |
| XBiotech Inc | 0.00 | -30.74m | 237.87m | 92.00 | -- | 1.14 | -- | -- | -1.01 | -1.01 | 0.00 | 6.87 | 0.00 | -- | -- | 0.00 | -13.08 | 31.88 | -13.68 | 33.27 | -- | -- | -- | 877.30 | -- | -- | 0.0456 | 0.00 | -100.00 | -- | 25.36 | -- | 24.30 | -- |
| Acrivon Therapeutics Inc | 0.00 | -64.12m | 238.37m | 58.00 | -- | 1.62 | -- | -- | -2.88 | -2.88 | 0.00 | 4.77 | 0.00 | -- | -- | 0.00 | -44.11 | -- | -46.46 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -93.76 | -- | -- | -- |
| Metagenomi Inc | 44.76m | -68.26m | 240.52m | 236.00 | -- | -- | -- | 5.37 | -1.82 | -1.82 | 1.19 | 5.73 | -- | -- | -- | 189,644.10 | -- | -- | -- | -- | -- | -- | -152.50 | -- | -- | -- | 0.00 | -- | 160.21 | -- | -56.57 | -- | -- | -- |
| Actinium Pharmaceuticals Inc | 81.00k | -46.45m | 244.82m | 49.00 | -- | 5.51 | -- | 3,022.47 | -1.72 | -1.72 | 0.003 | 1.49 | 0.0009 | -- | -- | 1,653.06 | -48.80 | -46.98 | -53.25 | -52.71 | -- | -- | -57,346.91 | -6,683.95 | -- | -- | 0.0006 | -- | -92.14 | -- | -47.86 | -- | 9.75 | -- |
| Emergent Biosolutions Inc | 1.19bn | -565.30m | 247.34m | 1.60k | -- | 0.3725 | -- | 0.2087 | -10.87 | -10.87 | 22.86 | 12.67 | 0.4988 | 1.99 | 6.09 | 740,875.00 | -23.79 | -2.94 | -38.89 | -3.66 | 41.19 | 53.24 | -47.69 | -5.95 | 0.5538 | 0.0636 | 0.5771 | -- | -6.10 | 6.05 | -259.40 | -- | -4.29 | -- |
| Enanta Pharmaceuticals Inc | 72.88m | -131.74m | 252.67m | 145.00 | -- | 1.52 | -- | 3.47 | -6.25 | -6.25 | 3.46 | 7.84 | 0.197 | -- | 5.70 | 502,627.60 | -35.60 | -14.56 | -40.33 | -15.62 | -- | -- | -180.75 | -54.96 | -- | -- | 0.0085 | -- | -8.07 | -17.45 | -9.91 | -- | 24.89 | -- |
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 11 Apr 2024 | 8.36m | 27.08% |
| Perceptive Advisors LLCas of 11 Apr 2024 | 5.36m | 17.37% |
| Citadel Advisors LLCas of 31 Mar 2024 | 1.65m | 5.34% |
| Wellington Management Co. LLPas of 31 Mar 2024 | 888.13k | 2.88% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 646.90k | 2.10% |
| Marshall Wace LLPas of 31 Mar 2024 | 597.47k | 1.94% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 497.32k | 1.61% |
| Geode Capital Management LLCas of 31 Mar 2024 | 242.85k | 0.79% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 133.28k | 0.43% |
| DAFNA Capital Management LLCas of 31 Mar 2024 | 131.35k | 0.43% |
